Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors

Paraskevi Diamanti,1,2 Benjamin C. Ede,2 Phoebe El Dace,2 William J. Barendt,2 Charlotte V. Cox,1 Jeremy P. Hancock,3 John P. Moppett4,4 and Allison Blair1,2
1Bristol Institute for Transfusion Sciences, NHSBT Filton, Bristol, 2School of Cellular and Molecular Medicine, University of Bristol, Bristol, 3Bristol Genetics Laboratory, Severn Pathology, North Bristol Trust, Bristol, UK, and 4Bristol Royal Hospital for Children, Bristol, UK

Received 23 January 2020; accepted for publication 1 May 2020
Correspondence: Dr Allison Blair, School of Cellular and Molecular Medicine, University Walk, University of Bristol, Bristol BS8 1TD, UK.
E-mail: allison.blair@bristol.ac.uk

Summary

Relapse of paediatric acute lymphoblastic leukaemia (ALL) may occur due to persistence of resistant cells with leukaemia-propagating ability (LPC). In leukaemia, the balance of B-cell lymphoma-2 (BCL-2) family proteins is disrupted, promoting survival of malignant cells and possibly LPC. A direct comparison of BCL-2 inhibitors, navitoclax and venetoclax, was undertaken on LPC subpopulations from B-cell precursor (BCP) and T-cell ALL (T-ALL) cases in vitro and in vivo. Responses were compared to BCL-2 levels detected by microarray analyses and Western blotting. In vitro, both drugs were effective against most BCP-ALL LPC, except CD34+/CD19- cells. In contrast, only navitoclax was effective in T-ALL and CD34+/CD7- LPC were resistant to both drugs. In vivo, navitoclax was more effective than venetoclax, significantly improving survival of mice engrafted with BCP- and T-ALL samples. Venetoclax was not particularly effective against T-ALL cases in vivo. The proportions of CD34+/CD19-, CD34+/CD19+ BCP-ALL cells and CD34+/CD7- T-ALL cells increased significantly following in vivo treatment. Expression of pro-apoptotic BCL-2 genes was lower in these subpopulations, which may explain the lack of sensitivity. These data demonstrate that some LPC were resistant to BCL-2 inhibitors and sustained remission will require their use in combination with other therapeutics.

Keywords: ALL, BCL-2, paediatric ALL, LPC, Navitoclax, Venetoclax, NSG.

Introduction

Treatment of childhood acute lymphoblastic leukaemia (ALL) has been very successful in recent years.1 However, relapse rates remain high in some subgroups.2-4 This may be due to the persistence of resistant clones or the emergence of clones following therapy that were not detected at diagnosis.5,6 We and others have previously identified ALL cells that have the ability to initiate and maintain the disease in murine models, known as leukaemia-propagating cells (LPC).7-15 A common finding, regardless of subtype, was that expression of antigens commonly associated with B-cell precursor (BCP)-ALL (CD34, CD10, CD19) or T-ALL (CD4, CD7) was not a prerequisite for disease-propagating ability in vivo. Indeed, we demonstrated that the frequency of LPC was often higher in CD34+/CD19- and CD34- subpopulations than in CD34+/CD19+ cells in BCP-ALL, with similar findings using CD34 and CD7 in T-ALL cases.12 Moreover, we have shown that some of these LPC populations, such as CD34+/CD19-, CD34+/CD7- and CD34- cells, can be resistant to treatment in vivo and in vitro.8,12,16 Hence, it is important to assess therapeutic agents on all LPC subpopulations that have capacity to cause relapse.

Bi-specific T-cell engagers and chimaeric antigen receptor T cells against CD19 have demonstrated the efficacy of immunotherapeutic approaches to treat ALL.17-20 However, such therapies cannot target LPC that lack CD19 and there is evidence of tumour escape, through lack of targeting, lineage switching and masking of the CD19 epitope.21,22 An alternative target of focus is B-cell lymphoma (BCL)-2, which has been shown to be overexpressed in >66% of BCP-ALL cases compared to normal bone marrow (NBM) donors23 and is associated with oncogenesis in several cancers.24,25 Consequently, BCL-2 inhibitors have been investigated in ALL.26-28 ABT-263 (navitoclax) binds to and inhibits BCL-2, BCL-extra large (BCL-xL) and Bcl-2-like...
protein 2 (BCL-w) and kills cells in a BCL-2-associated X protein (BAX)- and BCL-2-antagonist/killer protein (BAK)-dependent manner. However, thrombocytopenia caused by BCL-xL inhibition, compromises its use. ABT-199 (venetoclax) specifically inhibits BCL-2 allowing release of pro-apoptotic molecules. It does not bind to BCL-xL and consequently does not affect platelets.

Both navitoclax and venetoclax have been investigated in xenograft models of paediatric ALL with reports of extended survival of NOD.Cg-Prkdcscid/IL2r<sup>−/−</sup> tm1Wjl/SzJ (NSG) mice using navitoclax. Responses to venetoclax in BCP-ALL xenografts were more modest, although results improved when used in combination with vincristine and dexamethasone. To date, there is no information on the effects of BCL-2 inhibitors in LPC subpopulations, so the effects on potentially drug-resistant cells are unknown. Consequently, we have undertaken a direct comparison of navitoclax and venetoclax on unsorted cells and LPC from primary BCP- and T-ALL cases.

### Materials and methods

#### Samples

BM cells from children (median age, 7 years; range, 2–17) with BCP- (n = 20) and T-ALL (n = 11) at diagnosis or relapse were collected with approval of University Hospitals Bristol NHS Trust (Table I). NBM and cord blood (CB) were obtained from healthy donors. Mononuclear cells were cryopreserved as described. Viability on thawing was 69.6 ± 16.1% (ALL) and 73.0 ± 9.3% (normal) samples.

#### Cell sorting

BCP-ALL cells were stained with antibodies against CD34 (clone 8G12) and CD19 (clone 4G7). T-ALL cells were stained with anti-CD34 and anti-CD7 (clone M-T701). NBM and CB samples were stained with anti-CD34 and anti-CD38 (clone HB7, all BD Biosciences, Oxford, UK). Cells were

| Pt | Sub-type | Karyotype | Age at diagnosis (years) | Gender | Disease status at biopsy | MRD Risk† | Treatment protocol |
|----|----------|-----------|--------------------------|--------|--------------------------|-----------|-------------------|
| 1  | c-ALL    | Hyperdiploidy | 7                        | M      | D                        | High      | UKALL 2003        |
| 2  | Pre B    | t(12;21)  | 2                        | F      | D                        | Low       | UKALL 2003        |
| 3  | Pre B    | −1        | 2                        | F      | D                        | Low       | UKALL 2003        |
| 4  | Pre B    | t(9;22)   | 15                       | M      | D                        | Low       | UKALL 2003        |
| 5  | Pre B    | Hyperdiploidy | 2                      | M      | D                        | Low       | UKALL 2003        |
| 6  | Pre B    | 46XY      | 9                        | M      | D                        | High      | UKALL 2011        |
| 7  | Pre B    | t(12;21)  | 2                        | F      | D                        | Low       | UKALL 2011        |
| 8  | c-ALL    | t(12;21)  | 4                        | M      | D                        | ND        | UKALL 2011        |
| 9  | Pre B    | −9, +10, −18 | 2                   | F      | D                        | High      | UKALL 2003        |
| 10 | Pre B    | 46XY      | 14                       | F      | D                        | Int       | UKALL 2011        |
| 11 | Pre B    | +7, −9, −Y | 3                     | M      | D                        | Low       | UKALL 2011        |
| 12 | c-ALL    | t(12;21)  | 7                        | F      | D                        | Low       | UKALL 2011        |
| 13 | c-ALL    | +5        | 5                        | F      | D                        | Int       | UKALL 2011        |
| 14 | Pro B    | 11q23 rearr | 15                | F      | D                        | High      | UKALL 2011        |
| 15 | Pro B    | 11q23 rearr | 17             | F      | D                        | Int       | UKALL 2011        |
| 16 | Pre B    | t(12;21)  | 5                        | M      | D                        | Low       | UKALL 2011        |
| 17 | Pre B    | t(12;21)  | 3                        | M      | D                        | Low       | UKALL 2011        |
| 18 | Pre B    | PDGFRB rearr, −12p | 8           | F      | D                        | High      | UKALL 2011        |
| 19 | Pre B    | t(1;19)   | 12                       | M      | D                        | Low       | UKALL 2011        |
| 20 | c-ALL    | +5        | 17                       | M      | D                        | Low       | UKALL 2011        |
| 21 | T-ALL    | +4, +9    | 15                       | M      | D                        | High      | UKALL 2003        |
| 22 | T-ALL    | t(11;14)  | 12                       | M      | R                        | Low       | UKALL 2003        |
| 23 | T-ALL    | 46XY      | 17                       | M      | D                        | High      | UKALL 2003        |
| 24 | T-ALL    | −3, −6, −11, +1 | 2      | F      | D                        | ND        | UKALL 2011        |
| 25 | T-ALL    | t(1;14)   | 3                        | M      | D                        | Int       | UKALL 2011        |
| 26 | T-ALL    | 46XY      | 6                        | M      | D                        | Low       | UKALL 2011        |
| 27 | T-ALL    | −4, −9    | 9                        | M      | D                        | Low       | UKALL 2011        |
| 28 | T-ALL    | 46XY      | 7                        | M      | D                        | Int       | UKALL 2011        |
| 29 | T-ALL    | 21q22 rearr | 3            | M      | D                        | ND        | UKALL 2011        |
| 30 | T-ALL    | +7, +9, +14, +mar | 4       | M      | D                        | Low       | UKALL 2011        |
| 31 | T-ALL    | +ABL1     | 10                       | M      | D                        | Int       | UKALL 2011        |

D, diagnosis; Int, intermediate; ND, not determined; R, relapse. ALL, acute lymphoblastic leukaemia; c-ALL, common ALL; pre B, B-cell ALL; pro B, B-cell ALL; T-ALL, T-cell ALL. UKALL 2003; UKALL 2011.

†MRD risk status at day 29 for UKALL 2003 and at week 14 for UKALL 2011.
stained with propidium iodide (PI; Miltenyi Biotec, Bisley, UK) to exclude dead cells and live cells were sorted using a Becton Dickinson Influx cell sorter with BD software 1.2.0 (BD Biosciences, see Figure S1).

In vitro drug sensitivity

ALL and CB cells were treated with increasing concentrations of navitoclax or venetoclax for up to 48 h (Stratech Scientific Limited, Newmarket, UK), according to the manufacturer’s recommendations. Apoptosis and viability were assessed by flow cytometry using annexin V–fluorescein isothiocyanate and PI. Half-maximal inhibitory concentration (IC50) was calculated using non-linear regression analyses of dose response.

BCL-2 quantification

BCP-, T-ALL and CB cells were stained with anti-CD34 and one of the following: anti-CD19 (BCP-ALL), anti-CD7 (T-ALL) or anti-CD38 (CB) and viability dye eFluor 780 (Biologend, London, UK), fixed, permeabilised and stained with anti-human BCL-2 phycoerythrin (BD Biosciences), according to the manufacturer’s instructions. Samples were analysed using a MACS-Quant 10 flow cytometer (Miltenyi Biotec) with FlowJo software Version 7.10 (detailed in the supplemental file).

Western blotting

BCL-2 proteins were detected using mouse anti-human BCL-2, rabbit anti-human MCL1 (both New England Biolabs, Hitchin, UK) and mouse anti-human BCL-xL (Abcam, Cambridge, UK), all at 1:1000. IgG goat anti-rabbit-peroxidase (1:5000, Thermo Fisher Scientific, Loughborough, UK) or IgG sheep anti-mouse-peroxidase (1:10 000, GE Healthcare, Little Chalfont, UK) were used as secondary antibodies and levels were detected using luminescence substrate (BioRad, Watford, UK).

Microarray analyses

Gene expression analysis of BCP-, T-ALL and NBM samples was performed using Agilent Whole Human Genome Oligo Microarrays (Waldbronn, Germany), as previously described and detailed in supplementary files. Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress), accession number E-MTAB-4006.

In vivo studies

ALL was established in NSG mice using primary samples as described previously, and detailed in Data S1. Briefly, once the level of human cells in murine peripheral blood (PB) was ≥50%, animals were given BCL-2 inhibitors (100 mg/kg/day) for 21 days by oral gavage. Separate cohorts of mice were treated with standard chemotherapy or placebo. PB aspires were monitored weekly by flow cytometry and animals maintained until they began to exhibit symptoms of disease.

Statistical analyses

Full details are provided in Data S1.

Results

Effect of BCL-2 inhibitors in vitro

A range of responses to the pan-BCL-2 inhibitor, navitoclax, and the BCL-2-specific inhibitor, venetoclax, were observed (Fig. 1A). Eleven BCP-ALL cases (pts. 2, 6, 8, 9, 11, 14–17, 19, 20) were sensitive to navitoclax with a mean IC50 of 41 nmol/l (P ≤ 0.0001 cf. CB) and two were more resistant (pts. 10, 12, IC50 ≥ 693 nmol/l). Similar results were obtained in a cohort using venetoclax, where eight sensitive cases (pts. 6, 8, 9, 11, 14, 15, 17, 20) had a mean IC50 of 35 nmol/l (P ≤ 0.0001 cf. CB). Pts. 2, 16 and 19 were more resistant to venetoclax, although all three cases responded to navitoclax. Individual IC50 values are shown in Table S1. There was no significant difference in responses between measurable residual disease (MRD) low, intermediate or high risk groups (P = 0.52 for navitoclax and P = 0.37 for venetoclax).

All six T-ALL cases responded to navitoclax (mean IC50 69 nmol/l, P < 0.0001 cf. CB; Fig 1B). In contrast, five of these cases were resistant to venetoclax (IC50 496 nmol/l). The remaining case (pt. 29) responded to venetoclax at all doses tested (P = 0.004). Responses to navitoclax did not differ between MRD groups (P = 0.21); however intermediate and high risk samples were significantly more resistant to venetoclax (IC50 908 nmol/l, P = 0.02) than low risk cases (IC50 131 nmol/l).

Comparison of in vitro sensitivity and BCL-2 protein expression

To determine whether these responses were associated with BCL-2 expression, flow cytometric analyses were performed. The proportion of BCL-2+ cells was higher in BCP-ALL cases (60±23%) compared to T-ALL (32±8±32%), P = 0.1) and normal cells (27±2 ± 5%, P = 0.08, Fig 2A). Likewise, BCL-2 median fluorescence intensity (MFI) was significantly higher in BCP-ALL (median 190, range 35–397) than in T-ALL (62, range 23–109, P = 0.02) and >2-fold higher than normal cells (81, range 75–111, P = 0.09, Fig 2B). Western blotting confirmed BCL-2 expression was higher in BCP- than T-ALL cases and at least equivalent to that in normal CD19+ B cells (Fig 2C,D). Of the anti-apoptotic proteins, BCL-xL was the most prominent. Myeloid cell leukaemia 1 protein (MCL1 was present in all cases but did not differ from NBM cells, except in pt. 11, where higher levels were observed. BCL-w could not be detected in this cohort. Interestingly, pt. 2, who had the highest BCL-2, had the lowest sensitivity to both drugs. In T-ALL cases, BCL-2 levels were lower than normal T cells in 5/6 cases and comparable in pt. 29 (Fig 2D). The prosurvival proteins BCL-xL and MCL1 were expressed in most T-ALL cases but not in normal CD7+ cells. Amongst the samples that were more
sensitive to navitoclax, pts. 21, 25 & 29 had elevated levels of BCL-xL and MCL1. Pt. 29, who had the highest BCL-2 expression, was the only responder to venetoclax.

Response of LPC to BCL-2 inhibitors

Both inhibitors were subsequently assessed on recognised LPC subpopulations\(^7,10-12,16\) from a cohort of six BCP-ALL samples, including responders and less sensitive cases, and from all six T-ALL cases used previously. Unsorted cells and three of four BCP-ALL subpopulations (CD34\(^+\)/CD19\(^+\), CD34\(^+\)/CD19\(^-\) and CD34\(^-\)/CD19\(^+\)) responded to both inhibitors, with viability reduced to 1.6 ± 1.6% using 1 \(\mu\)mol/l navitoclax (IC\(_{50}\) range 18–54 nmol/l) and 2.4 ± 1.6% with venetoclax (IC\(_{50}\) range 3–120 nmol/l). In contrast, CD34\(^-\)/CD19\(^-\) LPC were more resistant to both drugs with 38.7 ± 29.3% cells surviving treatment with navitoclax and 27.4 ± 22.3% with venetoclax at the highest doses (Fig 3A). Individual results are shown in Table SII.

In T-ALL samples (Fig 3B), unsorted cells and three subpopulations (CD34\(^-\)/CD7\(^+\), CD34\(^-\)/CD7\(^-\) and CD34\(^+\)/CD7\(^-\)) responded to navitoclax (IC\(_{50}\) range 21–388 nmol/l) but not to the same extent as BCP-ALL cases. CD34\(^-\)/CD7\(^+\) cells were the most responsive (3.9 ± 2.7% viable using 1 \(\mu\)mol/l), while CD34\(^-\)/CD7\(^-\) cells were the least sensitive with 32.7 ± 27.9% surviving the highest dose. As was observed with the unsorted cells (Fig 1B), LPC from five cases were resistant to venetoclax. Only pt. 29 responded, although CD34\(^-\)/CD7\(^-\) LPC remained the least sensitive.

Differential expression of BCL-2 molecules

As navitoclax and venetoclax both affect other BCL-2 family members, gene expression levels of all anti-apoptotic and pro-apoptotic molecules were determined in a subset of cases and data compared to haemopoietic stem cells (HSC). There was no clear trend in upregulated or downregulated genes in ALL samples (Table II, Figures S2–S4). Some LPC had higher levels of anti-apoptotic genes (BCL-2 alpha, BCL-xL and BFL1/A1) than HSC. However, higher levels of pro-apoptotic genes including BMF (\(P \leq 0.01\)), BAD and BIM (\(P \leq 0.05\)), BAX (\(P = 0.05\)) and BCL2L13 were observed.
Navitoclax is superior to venetoclax in vivo

NSG mice with established leukaemia, from low, intermediate and high risk cases, were treated with navitoclax, venetoclax and, in some cases, standard chemotherapeutic agents (dexamethasone, vincristine, L-asparaginase ± daunorubicin). In BCP cases, navitoclax treatment decreased leukaemia burden or maintained it at the same level for 7–29 days from treatment start \((P < 0.001\), Fig 4A). Survival was extended up to 54 days. Using venetoclax, disease burden remained significantly below the levels in placebo groups in pts. 9 & 14 \((P < 0.0001)\) during treatment and for a further seven days in pt. 14. However, in pt. 4 (Ph°, low risk) disease burden significantly decreased to \(2.0 \pm 2.0\% \) \((P < 0.0001)\) and progression was significantly delayed by three weeks. Survival was improved with both drugs, particularly in pt. 4 (54 days, \(P = 0.01\)) with more modest improvements in pts. 9 & 14 (four days, \(P \leq 0.02\)). These responses were similar to those observed using standard induction therapy for 28 days.

In mice engrafted with T-ALL samples, navitoclax reduced disease burden and significantly delayed progression in all cases compared to controls \((P < 0.001\), Fig 4B). Survival in navitoclax-treated animals was extended by up to 40 days but disease burden was more effectively reduced using standard chemotherapeutics. Venetoclax had no effect on this T-ALL cohort.

Analyses of BM from terminated animals revealed an increase in the proportion of CD34+/CD19− cells following treatment with navitoclax \((8\text{-fold}, P \leq 0.01)\) and venetoclax \((13\text{-fold}, P \leq 0.03)\) in pt. 4 compared to the proportions in the diagnostic sample (Table III). In pts. 9 & 14, the proportions of CD34+/CD19− cells increased significantly following treatment with BCL-2 inhibitors \((P \leq 0.03)\) and following standard therapy, in pt 14 \((P = 0.002)\). In T-ALL cases, the CD34+/CD7− subpopulation, which was just detectable at diagnosis, had increased significantly in pt. 22, following treatment with both inhibitors \((P \leq 0.01)\). Likewise, in pt. 25, the majority of cells recovered from the BM were CD34+/CD7−, representing a >15-fold increase \((P < 0.004)\) in the proportion of these cells compared to the primary sample inoculated, while the CD34+/CD7− and CD34+/CD7− cells were significantly depleted \((P < 0.02)\). In pt. 31, in contrast, the CD7− subpopulations were most affected by treatment.
Discussion

Over the last decade there has been considerable interest in BCL-2 inhibitors for the treatment of cancers. However, their efficacy has not been assessed on LPC subpopulations, which have variable repopulating capacity, and some are refractory to treatment with conventional (dexamethasone, vincristine) and novel therapeutics, such as parthenolide and Hsp90 inhibitors. This is the first report directly comparing the sensitivity of paediatric BCP- and T-ALL samples and their respective LPC subpopulations to navitoclax and venetoclax.

BCL-2, BCL-xL and other BCL-2 family proteins were differentially expressed in ALL pts., resulting in a range of responses to BCL-2 inhibitors. In BCP-ALL, 8/11 samples were sensitive to both drugs in vitro and three cases responded to navitoclax only. In contrast, all six T-ALL cases responded to navitoclax but only one case responded to venetoclax.

Most BCP LPC subpopulations responded to both drugs, but more so navitoclax, with the exception of CD34+/CD19- cells. T-ALL LPC were also responsive to navitoclax, although CD34+/CD7- LPC were the least sensitive. In contrast, venetoclax was not effective against T-ALL LPC, with the exception of one pt. where the drug killed most LPC.
Table II. Median fold change in expression of BCL-2 genes in ALL compared to normal BM.

| Gene    | BCP-ALL | T-ALL |
|---------|---------|-------|
|         | Unsorted | CD34+/CD19+ | CD34+/CD19+ | CD34+/CD19+ | CD34+/CD19+ |
| Anti-apoptotic |         |         |         |         |         |
| BCL-2 alpha | 2.3 | 1.6 | -1.8 | 1.2 | 1.6 |
| BCL-2 beta | -1.2 | -2.5 | -1.5 | -2.1 | -1.9 |
| BCL-xL    | -1.7 | 1.2 | 1.0 | -6.0 | -2.0 |
| BCL-w     | 3.7 | 1.8 | -1.1 | 2.0 | -2.5 |
| MCL1      | 2.5 | -1.7 | -1.2 | -1.2 | 1.4 |
| BFL1/A1   | -1.7 | 2.3 | 1.5 | 5.7 | 2.2 |
| Pro-apoptotic |         |         |         |         |         |
| BAX beta  | 2.2 | 1.5 | 1.4 | 1.3 | 1.4 |
| BAX sigma | -1.0 | 1.2 | 1.3 | 1.0 | 1.2 |
| BAK1      | 1.0 | -2.5 | -1.3 | -1.2 | -2.3 |
| BOK       | -1.8 | -1.7 | 1.1 | -1.6 | -1.5 |
| BAD       | 2.0 | -1.6 | 2.1 | -1.7 | -2.0 |
| BIK       | 4.2 | -1.8 | -4.1 | -7.3 | -2.6 |
| NOXA      | 1.4 | 1.4 | 1.6 | 1.2 | 1.4 |
| HRK       | 1.3 | 1.2 | -2.0 | -1.5 | -4.0 |
| PUMA      | -1.8 | 1.1 | 2.1 | -1.1 | 1.2 |
| BMF       | 2.8 | 5.0*** | 5.5*** | 3.4** | 2.1 |
| BID       | 3.6 | 1.5 | -1.4 | 2.4 | 2.0 |
| BIM var1  | -1.0 | -1.7 | -2.4 | -2.6 | -1.4 |
| BIM var9  | 4.7** | 2.0 | 2.5 | 1.5 | 1.6 |
| BCL2L13   | 2.0 | 1.2 | 1.2 | 1.3 | 1.4 |
| CASP9     | -1.6 | -3.5 | -2.7 | -1.9 | -3.2 |

Table II. (Continued)

| Gene    | T-ALL | Unsorted | CD34+/CD7+ | CD34+/CD7+ | CD34+/CD7+ | CD34+/CD7+ |
|---------|-------|----------|------------|------------|------------|------------|
|         |       |          | CD34+/CD7+ | CD34+/CD7+ | CD34+/CD7+ | CD34+/CD7+ |
| Anti-apoptotic |       |          |           |           |           |           |
| BCL2L13 | 1-6   | 2.1**    | 1-6        | 2.3**      | -1-5       |
| CASP9   | 1-3   | -4-1     | -8.8       | -3-6       | -3-6***    |
| Pro-apoptotic |       |          |           |           |           |           |

with limited effects on the CD34+/CD7- subpopulation. Our varied findings in vitro are in agreement with reports on the activity of venetoclax in ALL cell lines and patient derived xenograft (PDX) samples,36,41 acute myeloid leukaemia cell lines,36,42 and of navitoclax in ALL cell lines.34 The lack of response of T-ALL cases to venetoclax also concurs with the findings by of Changaile et al., who reported that only the early T-cell precursor (ETP) subtype was sensitive to venetoclax, indicating this phenotype may be BCL-2-dependent.43

The reason why a sample responds to navitoclax and not venetoclax may be due to varied expression of BCL-2 targets. All BCP cases investigated had high levels of BCL-2, BCL-xL and MCL1, in accordance with previous reports,26,35 and responded to navitoclax. Likewise, T-ALL cases that responded to navitoclax had higher levels of BCL-xL and/or MCL1. BCL-2 expression was higher in BCP- than in T-ALL samples, which may explain why more BCP-ALL samples responded to venetoclax. Indeed, venetoclax sensitivity in BCP-ALL has been linked to high expression of BCL-2 and lower expression of MCL1.41 In the present study, venetoclax resistance in T-ALL may be associated with low levels of BCL-2.36,37 The single T-ALL case that responded to both drugs was the only one with high BCL-2, although it was not ETP subtype.

In LPC, the moderately higher levels of BCL-2 in CD34+/CD19- and CD34+/CD7- cells seem at odds with the lack of response of these cells. However, inhibition of one BCL-2 protein can cause partner swapping and change the original dependence of the cell.44 Upregulation of pro-apoptotic genes, BAD and BIM in particular, may also be required to sensitize cells to BCL-2 inhibitors.41,42,43 However, both were downregulated in CD34+/CD19- cells. The pro-apoptotic gene BMF was significantly upregulated in three of four BCP LPC populations, which...
might explain the higher sensitivity of those LPC compared to CD34+/CD19− cells. Overexpression of CTLA4, ITGB2 and MAP2K7, together with lack of expression of CHEK2 may also explain the resistance observed in this subpopulation.46,47

In T-ALL LPC, higher levels of BCL-2, BCL-xL, BFL1/A1, PAK2 and tumour suppressor activated protein C (APC) were found. Increased expression of such prosurvival proteins may have reduced the efficacy of venetoclax, as has been reported in other malignancies.36,45,48,49 However, high levels of prosurvival proteins did not correlate with venetoclax insensitivity in a study on BCP PDX samples.41 It is possible that the very low levels of pro-apoptotic BAD, BIK and CASP-9 genes in CD34+/CD19− cells may contribute to resistance.

Venetoclax has been reported to have broad efficacy in xenograft models of paediatric ALL, with survival extended by 25–30 days,34,35 with more modest effects using venetoclax.36 In our direct comparison, the majority of samples responded to navitoclax in vivo, with extended survival observed in both subtypes. While venetoclax improved survival in BCP engrafted mice, it was ineffective on those

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

| Pt, ID | Time point | Proportion of nucleated cells (%) |
|-------|------------|---------------------------------|
|       |            | CD34+/CD19− | CD34+/CD19+ | CD34+/CD19− | CD34+/CD19+ |
| BCP-ALL |            |                 |                |                |
| 4     | Diagnosis  | 85              | 0.7           | 7             | 7 |
|       | Navitoclax | 72 ± 11         | 6 ± 3*        | 21 ± 12       | 2 ± 1 |
|       | Venetoclax | 76 ± 1          | 10 ± 6*       | 13 ± 7        | 1 ± 0.2 |
| 9     | Diagnosis  | 1·8             | 0·2           | 93·9          | 4·1 |
|       | Navitoclax | 1 ± 1           | 0·4 ± 0·1     | 92 ± 1        | 8 ± 0·5* |
|       | Venetoclax | 1 ± 1           | 0·2 ± 0·1     | 86 ± 1        | 13 ± 1* |
|       | Std Chem   | 0·5 ± 0·4*      | 0·5 ± 0·2     | 52 ± 41       | 47 ± 41 |
| 14    | Diagnosis  | 25              | 0·5           | 72·6          | 1·9 |
|       | Navitoclax | 9 ± 2           | 2 ± 2         | 78 ± 11       | 12 ± 9* |
|       | Venetoclax | 11 ± 5          | 1 ± 0·4       | 77 ± 4        | 10 ± 4* |
|       | Std Chem   | 0·9 ± 0·1***    | 0·1 ± 0·01    | 87 ± 0·7      | 12 ± 0·9** |
| T-ALL |            |                 |                |                |
| 22    | Diagnosis  | 0·1             | 0             | 99            | 0·05 |
|       | Navitoclax | 0              | 0             | 93 ± 1        | 7 ± 1** |
|       | Venetoclax | 0              | 0             | 85 ± 5        | 15 ± 5** |
|       | Std Chem   | 0·9 ± 0·03      | 0·1 ± 0·1     | 77 ± 14       | 22 ± 14 |
| 25    | Diagnosis  | 20·1            | 0·3           | 75·2          | 4·4 |
|       | Navitoclax | 0·2 ± 0·2**     | 0·4 ± 0·4     | 31 ± 2*       | 68 ± 1** |
|       | Venetoclax | 0              | 0             | 33*           | 67** |
|       | Std Chem   | 0·6 ± 0·1***    | 0·4 ± 0·1     | 68 ± 9        | 31 ± 9** |
| 31    | Diagnosis  | 2              | 14            | 34            | 50 |
|       | Navitoclax | 9 ± 5           | 2 ± 2         | 67 ± 27       | 22 ± 17 |
|       | Venetoclax | 28 ± 13         | 2 ± 1         | 65 ± 22       | 5 ± 3 |

Data shows the immunophenotype of primary patient samples at diagnosis and the immunophenotype of cells recovered from the bone marrow of NSG mice engrafted with these patient samples then treated with navitoclax, venetoclax or standard chemotherapeutics (Std Chem: dexamethasone, vincristine, L-asparaginase & daunorubicin). Bold text indicates significant difference from inoculated primary sample (*, P ≤ 0·05; **, P ≤ 0·01; ***, P ≤ 0·001; ****, P ≤ 0·0001).

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.

Table III. Immunophenotype of patient cells at diagnosis and those recovered from treated NSG mice.
The lack of response of T-ALL cases to venetoclax concurs with previous reports, although Seyfried et al. reported delayed progression in one of three PDX samples. The superior effects of navitoclax in vivo support the findings of Khaw et al., and concur with our findings in vitro. However, in two BCP-ALL cases (intermediate and high risk), promising responses to both drugs in vitro were not confirmed in vivo, where effects were transient at best.

Since the LPC populations only had moderate responses to navitoclax in vitro, with T-ALL LPC largely unaffected by venetoclax, and sustained remission in treated mice was lacking, direct in vivo investigations using these inhibitors on LPC were not pursued. However, the proportions of LPC recovered from murine BM were compared to those on LPC were not pursued. Nonetheless, in intermediate and high risk BCP cases, the proportions of CD34+/CD19- cells increased significantly following treatment with BCL-2 inhibitors and standard therapeutics, while CD34+/CD19- cells increased in the low risk case. This concur with our findings in vitro and provides robust functional evidence of resistance in the CD34+/CD19- subpopulation. Likewise, a significant increase in CD34+/CD7- cells was observed in T-ALL cases, analogous to the poor in vitro response observed in this subpopulation, with a corresponding decrease in the proportion of CD7- cells. We have previously shown that some LPC subpopulations (CD34+/CD19- in BCP-ALL and CD34+/CD7- and CD34- in T-ALL), that have self-renewal capacity over several generations in NSG mice, are resistant to therapy. The results in this study add to the evidence of refractoriness in these subpopulations, which would also be resistant to chimeric antigen receptor (CAR) T cells directed at CD19 or CD7. Therefore, alternative therapeutic options will be required to eradicate these subpopulations.

Collective results indicate that BH3 mimetics may not be effective as single agents for paediatric leukaemias, especially as the LPC subpopulations expressed BCL-2 genes at various levels. An alternative approach may be to combine BH-3 mimetics with inhibitors of survival pathways (e.g. tyrosine kinase inhibitors) to increase apoptosis with potentially fewer side effects than using conventional cytotoxic therapies.

Acknowledgements

The authors wish to thank Mr Paul Archer at Bristol Genetics Laboratory, the oncology staff at Bristol Royal Hospital for Children and Dr Andrew Herman and Miss Lorena Sueiro Ballesteros at the University of Bristol Faculty of Life Sciences Flow Cytometry Facility. We are grateful to the patients and their families who gave permission for their cells to be used for research.

Funding information

This article presents independent research commissioned by the National Institute for Health Research (NIHR) under its Programme Grants scheme (RP-PG-0310-1003) and its Blood and Transplant Unit (NIHR BTRU) in stem cell transplantation and immunotherapy at University of Bristol in partnership with NHS Blood and Transplant. Support was also provided by the Wellcome Trust Institutional Strategic Support Fund through the Elizabeth Blackwell Institute, University of Bristol and NHS Blood and Transplant.

Author contributions

PD conceived study, designed and performed experiments and wrote the report. BCE processed samples, designed and performed experiments and commented on the report. PEID performed experiments and commented on the report. WJB performed experiments and commented on the report. CVC processed samples and commented on the report. JPH performed MRD testing on patient samples and commented on the report. JPM facilitated sample collection, collated the clinical data information and commented on the report. AB conceived and designed the study, performed in vivo experiments and wrote the report.

Conflict of interests

The authors declare to have no potential conflicts of interest regarding the present work.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Supplemental methods.

Table S1. IC50 values of individual patient samples following BCL-2 inhibitor treatment.

Table SII. Proportions of LPC subpopulation in individual samples and IC50 values following BCL-2 inhibitor treatment.

Table SIII. Median fold change in expression of genes in acute lymphoblastic leukaemia (ALL) LPC compared to normal HSC.

Fig S1. Gating strategy for sorting leukaemia subpopulations.

Fig S2. Expression of anti-apoptotic and pro-apoptotic BCL-2 genes in BCP acute lymphoblastic leukaemia (ALL) and normal cells.

Fig S3. Microarray analysis of anti-apoptotic and pro-apoptotic BCL-2 genes in T-cell acute lymphoblastic leukaemia (T-ALL) and normal cells.

Fig S4. Functional grouping of differentially expressed genes.
References

1. Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:3928–48.

2. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukaemia Consortium study. J Clin Oncol. 2010;28:648–54.

3. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynor PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371–81.

4. Ceppi F, Duval M, Leclerc IM, Lavenderi C, Delva YL, Cellot S, et al. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. PLoS ONE. 2011;6:e216301.

5. Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bjarnason A, et al. In childhood acute lymphoblastic leukaemia involving selection of a preexisting drug-resistant subclone. Blood. 2007;110:632–9.

6. Peirs S, Frisamant V, Matthijsens F, van Loosoe W, Pieters T, Vandamme N, et al. Targeting BCL2 proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017;31:2037–47.

7. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, et al. Identification of CD34+ cells in human acute lymphoblastic leukemia. Blood. 2010;116:5268–79.

8. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia. 2011;25:1249–58.

9. Diament P, Cox CV, Blair A. Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice. Leukemia. 2012;26:375–80.

10. Diament P, Cox CV, Moppett JP, Blair A. Parthenolide inhibits leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. Blood. 2013;123:1384–93.

11. Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med. 2013;5:38–51.

12. Aoki Y, Watanabe T, Saito Y, Kuroki Y, Hiyakata A, Takagi M, et al. Identification of CD34+ and CD34− leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood. 2012;123:967–80.

13. Cox CV, Diament P, Moppett JP, Blair A. Investigating CD34 expression in leukemia propagating cells in childhood T cell acute lymphoblastic leukemia. PLoS ONE. 2011;6:e165210.

14. Diament P, Cox CV, Moppett JP, Blair A. Dual targeting of Hop90 in childhood acute lymphoblastic leukaemia. Br J Haematol. 2014;180:147–9.

15. Kantarjian HM, Deangelio DJ, Steljes M, Martinelli G, Liedke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2013;367:740–53.

16. Bertaina A, Vinti L, Strocchi L, Gaspari S, Caruso R, Algeri M, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukemia of childhood. Br J Haematol. 2017;176:629–36.

17. von Stackelberg A, Locatelli F, Zugaiafer G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/Phase II study of bisatunomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–9.

18. Wei G, Ding L, Wang J, Hu Y, Huang H. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/refractory acute lymphoblastic leukemia. Exp Hematol Oncol. 2017;6:10.

19. Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–10.

20. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24:1499–503.

21. Menendez P, Vargas A, Bueno C, Barrena S, Almeida J, de Santiago M, et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia. 2004;18:491–8.

22. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398–406.

23. Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109.

24. Allford SE, Kothari A, Loffe EC, Eichhorn JM, Sakurinkar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75:1366–75.

25. Del Gaizo Moore V, Schilling KD, Sallan SE, Armstrong SA & Letai F. A BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111:2300–9.

26. Peirs S, Matthijsens F, Goussens S, van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738–47.

27. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389–99.

28. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009;16:1030–9.

29. Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826–33.

30. Souers AJ, Levenson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.

31. del Poeta G, Postorino M, Pupo L, del Principe MI, bal Do M, Bittolo T, et al. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs Today (Barc). 2016;52:249–60.

32. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1181–9.

33. Suryani S, Carol H, Chonghaile TN, Frisamant V, Sarmach C, High L, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20:4520–31.

34. Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged B-cell leukemia. Blood. 2016;128:1382–95.

35. Frisamant V, Debay MF, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129:e26–37.

36. Lam LT, Zhang H, Xue J, Levenson JD, Blathena A. Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Nota-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. Cancer Cell Int. 2015;15:5.

37. Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan Y, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078.

38. Inao T, lida Y, Moritani T, Okimoto T, Tanino R, Katoh N, et al. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget. 2018;9:25545–56.
41. Seyfried F, Demir S, Horl RL, Stirnweiss FU, Ryan J, Scheffold A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. *Cell Death Dis*. 2019;10:571.
42. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. *Cancer Discov*. 2014;4:362–75.
43. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. *Cancer Discov*. 2014;4:1074–87.
44. Soderquist RS, Eastman A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. *Mol Cancer Therap*. 2016;15:2011–7.
45. Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, et al. Bcl-2 is a therapeutic target for hypodiploid B-Lineage acute lymphoblastic leukemia. *Cancer Res*. 2019;79:2339–51.
46. Shishido S, Bonig H, Kim YM. Role of integrin alpha4 in drug resistance of leukemia. *Front Oncol*. 2014;4:99.
47. Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. *Br J Haematol*. 2007;136:269–75.
48. Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. *Mol Cancer Ther*. 2016;15:1132–44.
49. Marlin JW, Eaton A, Montano GT, Chang YW, Jakobi R. Elevated p21-activated kinase 2 activity results in anchorage-independent growth and resistance to anticancer drug-induced cell death. *Neoplasia*. 2009;11:286–97.